UK markets closed
  • NIKKEI 225

    29,215.52
    +190.06 (+0.65%)
     
  • HANG SENG

    25,787.21
    +377.46 (+1.49%)
     
  • CRUDE OIL

    83.34
    +0.90 (+1.09%)
     
  • GOLD FUTURES

    1,770.60
    +4.90 (+0.28%)
     
  • DOW

    35,426.49
    +167.88 (+0.48%)
     
  • BTC-GBP

    45,846.84
    +724.79 (+1.61%)
     
  • CMC Crypto 200

    1,468.45
    +5.10 (+0.35%)
     
  • ^IXIC

    15,130.10
    +108.29 (+0.72%)
     
  • ^FTAS

    4,119.18
    +9.01 (+0.22%)
     

Abivax announces the release of its 2021 half-year financial report

·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

DGAP-News: ABIVAX / Key word(s): Half Year Report
30.09.2021 / 18:00
The issuer is solely responsible for the content of this announcement.

Abivax announces the release of its 2021 half-year financial report

PARIS, France, September 30, 2021 - 6:00 pm (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces the publication of its 2021 half-year financial report. This document is available in electronic version on the website of the company (www.abivax.com - "Investors") and on the website of the French financial markets authority, AMF (www.amf-france.org).

*****

About Abivax (www.abivax.com)
Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe chronic inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.


Contacts

Abivax
Communications
Regina Jehle
regina.jehle@abivax.com
+33 6 24 50 69 63

Investors
LifeSci Advisors
Ligia Vela-Reid
lvela-reid@lifesciadvisors.com
+44 7413 825310

Press Relations & Investors Europe
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22

Public Relations France
Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 6 21 10 49 24

Public Relations France
DGM Conseil
Thomas Roborel de Climens
thomasdeclimens@dgm-conseil.fr
+33 6 14 50 15 84

Public Relations USA
Rooney Partners LLC
Jeanene Timberlake
jtimberlake@rooneypartners.com
+1 646 770 8858


30.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting